drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00529 | DB00675 | 789 | 888 | [
"DDInter779",
"DDInter1744"
] | Foscarnet | Tamoxifen | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Moderate | 1 | [
[
[
789,
24,
888
]
],
[
[
789,
24,
543
],
[
543,
63,
888
]
],
[
[
789,
21,
29152
],
[
29152,
60,
888
]
],
[
[
789,
23,
112
],
[
112,
... | [
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
... | Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen
Foscarnet (Compound) causes Thirst (Side Effect) and Thirst (Side Effect) is caused by Tamoxifen (Compound)
Foscar... |
DB00261 | DB00712 | 702 | 1,274 | [
"DDInter93",
"DDInter764"
] | Anagrelide | Flurbiprofen (ophthalmic) | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Flurbiprofen can cause developmental toxicity and female reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
702,
24,
1274
]
],
[
[
702,
24,
1119
],
[
1119,
1,
1274
]
],
[
[
702,
24,
935
],
[
935,
63,
1274
]
],
[
[
702,
7,
3218
],
[
3218,
... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlordiazepoxide"
],
... | Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Chlordiazepoxide and Chlordiazepoxide (Compound) resembles Flurbiprofen (Compound)
Anagrelide may cause a moderate interactio... |
DB08875 | DB11866 | 1,618 | 1,068 | [
"DDInter262",
"DDInter1618"
] | Cabozantinib | Romosozumab | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapies. Romosozumab prevents bone resorption and induces the formation of bone though it... | Moderate | 1 | [
[
[
1618,
24,
1068
]
],
[
[
1618,
64,
1069
],
[
1069,
24,
1068
]
],
[
[
1618,
63,
1195
],
[
1195,
24,
1068
]
],
[
[
1618,
25,
292
],
[
292... | [
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romosozumab"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vande... | Cabozantinib may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib may cau... |
DB00687 | DB09104 | 870 | 286 | [
"DDInter747",
"DDInter1118"
] | Fludrocortisone | Magnesium hydroxide | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
870,
24,
286
]
],
[
[
870,
24,
1482
],
[
1482,
23,
286
]
],
[
[
870,
63,
88
],
[
88,
23,
286
]
],
[
[
870,
62,
1018
],
[
1018,
2... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxi... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Metopr... |
DB00872 | DB06626 | 1,080 | 263 | [
"DDInter438",
"DDInter147"
] | Conivaptan | Axitinib | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Major | 2 | [
[
[
1080,
25,
263
]
],
[
[
1080,
24,
379
],
[
379,
23,
263
]
],
[
[
1080,
25,
392
],
[
392,
24,
263
]
],
[
[
1080,
25,
1593
],
[
1593,
... | [
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axitinib"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
],
[
"Rabeprazole... | Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole may cause a minor interaction that can limit clinical effects when taken with Axitinib
Conivaptan may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a mo... |
DB00673 | DB01124 | 723 | 1,411 | [
"DDInter112",
"DDInter1828"
] | Aprepitant | Tolbutamide | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
723,
24,
1411
]
],
[
[
723,
24,
959
],
[
959,
40,
1411
]
],
[
[
723,
63,
245
],
[
245,
40,
1411
]
],
[
[
723,
6,
10215
],
[
10215,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound... |
DB00468 | DB01015 | 1,424 | 1,247 | [
"DDInter1557",
"DDInter1724"
] | Quinine | Sulfamethoxazole | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Minor | 0 | [
[
[
1424,
23,
1247
]
],
[
[
1424,
63,
10
],
[
10,
1,
1247
]
],
[
[
1424,
6,
3486
],
[
3486,
45,
1247
]
],
[
[
1424,
21,
28804
],
[
28804,
... | [
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
],
[
"... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone (Compound) resembles Sulfamethoxazole (Compound)
Quinine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sulfamethoxazole (Compound)
Quinine (Compound) causes Purpura (Side Effect) and Purpura (Side ... |
DB00065 | DB00570 | 581 | 147 | [
"DDInter923",
"DDInter1936"
] | Infliximab | Vinblastine | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Major | 2 | [
[
[
581,
25,
147
]
],
[
[
581,
25,
134
],
[
134,
24,
147
]
],
[
[
581,
25,
970
],
[
970,
23,
147
]
],
[
[
581,
25,
37
],
[
37,
62,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinblastine"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u... | Infliximab may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Infliximab may lead to a major life threatening interaction when taken with Fluorouracil and Fluorouracil may cause a minor ... |
DB09049 | DB11837 | 1,135 | 1,297 | [
"DDInter1261",
"DDInter1351"
] | Naloxegol | Osilodrostat | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Minor | 0 | [
[
[
1135,
23,
1297
]
],
[
[
1135,
24,
1320
],
[
1320,
63,
1297
]
],
[
[
1135,
63,
353
],
[
353,
24,
1297
]
],
[
[
1135,
62,
578
],
[
578,
... | [
[
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osilodrostat"
]
],
[
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
... | Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofu... |
DB00209 | DB00408 | 352 | 1,408 | [
"DDInter1886",
"DDInter1099"
] | Trospium | Loxapine | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | An antipsychotic agent used in schizophrenia. [PubChem] | Moderate | 1 | [
[
[
352,
24,
1408
]
],
[
[
352,
24,
695
],
[
695,
40,
1408
]
],
[
[
352,
24,
1178
],
[
1178,
1,
1408
]
],
[
[
352,
6,
7992
],
[
7992,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loxapine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
"Cl... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Loxapine (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Loxapine (Compound)
... |
DB06043 | DB10795 | 1,644 | 221 | [
"DDInter1328",
"DDInter1486"
] | Olaratumab | Poliovirus type 1 antigen (formaldehyde inactivated) | Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Stu... | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
1644,
24,
221
]
],
[
[
1644,
64,
581
],
[
581,
24,
221
]
],
[
[
1644,
63,
599
],
[
599,
24,
221
]
],
[
[
1644,
24,
1531
],
[
1531,
... | [
[
[
"Olaratumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Olaratumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"... | Olaratumab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken... |
DB00006 | DB00285 | 942 | 1,100 | [
"DDInter217",
"DDInter1927"
] | Bivalirudin | Venlafaxine | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Moderate | 1 | [
[
[
942,
24,
1100
]
],
[
[
942,
24,
643
],
[
643,
40,
1100
]
],
[
[
942,
25,
235
],
[
235,
63,
1100
]
],
[
[
942,
24,
366
],
[
366,
... | [
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
]
],
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
],
... | Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine (Compound) resembles Venlafaxine (Compound)
Bivalirudin may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a moderate interaction that could exace... |
DB00741 | DB09564 | 167 | 1,296 | [
"DDInter885",
"DDInter930"
] | Hydrocortisone | Insulin degludec | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
167,
24,
1296
]
],
[
[
167,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
167,
23,
659
],
[
659,
24,
1296
]
],
[
[
167,
63,
1645
],
[
1645,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Vilante... |
DB00331 | DB09074 | 1,645 | 1,362 | [
"DDInter1164",
"DDInter1327"
] | Metformin | Olaparib | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
1645,
24,
1362
]
],
[
[
1645,
63,
168
],
[
168,
24,
1362
]
],
[
[
1645,
24,
1619
],
[
1619,
63,
1362
]
],
[
[
1645,
24,
473
],
[
473,
... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib m... |
DB00738 | DB09104 | 485 | 286 | [
"DDInter1420",
"DDInter1118"
] | Pentamidine | Magnesium hydroxide | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
485,
24,
286
]
],
[
[
485,
24,
820
],
[
820,
23,
286
]
],
[
[
485,
63,
355
],
[
355,
23,
286
]
],
[
[
485,
24,
859
],
[
859,
24,... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
... | Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Lactulose ... |
DB00580 | DB01088 | 311 | 714 | [
"DDInter1910",
"DDInter908"
] | Valdecoxib | Iloprost | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
311,
24,
714
]
],
[
[
311,
24,
1479
],
[
1479,
24,
714
]
],
[
[
311,
63,
1432
],
[
1432,
24,
714
]
],
[
[
311,
24,
1564
],
[
1564,
... | [
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
... | Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Abc... |
DB00363 | DB00619 | 695 | 1,419 | [
"DDInter419",
"DDInter909"
] | Clozapine | Imatinib | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Major | 2 | [
[
[
695,
25,
1419
]
],
[
[
695,
6,
4973
],
[
4973,
45,
1419
]
],
[
[
695,
18,
5527
],
[
5527,
57,
1419
]
],
[
[
695,
24,
222
],
[
222,
... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
]
],
[
[
"Clozapine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Imatinib"
... | Clozapine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Imatinib (Compound)
Clozapine (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Imatinib (Compound)
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause ... |
DB00467 | DB00653 | 1,467 | 544 | [
"DDInter644",
"DDInter1120"
] | Enoxacin | Magnesium sulfate | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions... | Moderate | 1 | [
[
[
1467,
24,
544
]
],
[
[
1467,
24,
1473
],
[
1473,
63,
544
]
],
[
[
1467,
25,
175
],
[
175,
24,
544
]
],
[
[
1467,
40,
246
],
[
246,
... | [
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
]
],
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium gluconate"
... | Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate and Magnesium gluconate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate
Enoxacin may lead to a major life threatening interaction when taken with Triamcinolone a... |
DB00531 | DB01059 | 450 | 956 | [
"DDInter456",
"DDInter1313"
] | Cyclophosphamide | Norfloxacin | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Minor | 0 | [
[
[
450,
23,
956
]
],
[
[
450,
23,
872
],
[
872,
40,
956
]
],
[
[
450,
62,
1176
],
[
1176,
1,
956
]
],
[
[
450,
23,
1539
],
[
1539,
... | [
[
[
"Cyclophosphamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
... | Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound)
Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Norfl... |
DB00377 | DB01599 | 1,494 | 1,232 | [
"DDInter1382",
"DDInter1523"
] | Palonosetron | Probucol | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). | Moderate | 1 | [
[
[
1494,
24,
1232
]
],
[
[
1494,
23,
112
],
[
112,
23,
1232
]
],
[
[
1494,
24,
1555
],
[
1555,
24,
1232
]
],
[
[
1494,
24,
927
],
[
927,
... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Probucol"
]
],
[
[
"Palonosetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Probucol
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and O... |
DB00468 | DB05239 | 1,424 | 866 | [
"DDInter1557",
"DDInter425"
] | Quinine | Cobimetinib | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Moderate | 1 | [
[
[
1424,
24,
866
]
],
[
[
1424,
24,
214
],
[
214,
63,
866
]
],
[
[
1424,
63,
1051
],
[
1051,
24,
866
]
],
[
[
1424,
24,
888
],
[
888,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and ... |
DB00099 | DB00352 | 440 | 482 | [
"DDInter735",
"DDInter1814"
] | Filgrastim | Tioguanine | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Moderate | 1 | [
[
[
440,
24,
482
]
],
[
[
440,
24,
869
],
[
869,
63,
482
]
],
[
[
440,
63,
1648
],
[
1648,
24,
482
]
],
[
[
440,
24,
552
],
[
552,
2... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesle... |
DB00502 | DB01169 | 1,300 | 57 | [
"DDInter853",
"DDInter120"
] | Haloperidol | Arsenic trioxide | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Major | 2 | [
[
[
1300,
25,
57
]
],
[
[
1300,
6,
8374
],
[
8374,
45,
57
]
],
[
[
1300,
23,
112
],
[
112,
23,
57
]
],
[
[
1300,
24,
603
],
[
603,
6... | [
[
[
"Haloperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Haloperidol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Haloperidol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Arsenic trioxide (Compound)
Haloperidol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Arsenic trioxide
Ha... |
DB00790 | DB01143 | 664 | 923 | [
"DDInter1431",
"DDInter65"
] | Perindopril | Amifostine | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. | Moderate | 1 | [
[
[
664,
24,
923
]
],
[
[
664,
21,
28642
],
[
28642,
60,
923
]
],
[
[
664,
40,
610
],
[
610,
24,
923
]
],
[
[
664,
24,
714
],
[
714,
... | [
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Perindopril",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effect) is caused by ... | Perindopril (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Amifostine (Compound)
Perindopril (Compound) resembles Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Perindopril may cause a moderate interaction that co... |
DB00163 | DB01166 | 1,461 | 477 | [
"DDInter1943",
"DDInter379"
] | Vitamin E | Cilostazol | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
1461,
24,
477
]
],
[
[
1461,
24,
126
],
[
126,
23,
477
]
],
[
[
1461,
24,
51
],
[
51,
24,
477
]
],
[
[
1461,
24,
936
],
[
936,
6... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
... | Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin... |
DB06343 | DB08882 | 1,379 | 1,281 | [
"DDInter1766",
"DDInter1070"
] | Teprotumumab | Linagliptin | Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016 and was approved by th... | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
1379,
24,
1281
]
],
[
[
1379,
63,
1002
],
[
1002,
1,
1281
]
],
[
[
1379,
63,
1685
],
[
1685,
24,
1281
]
],
[
[
1379,
24,
1296
],
[
129... | [
[
[
"Teprotumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Teprotumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
... | Teprotumumab may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Teprotumumab may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction... |
DB00970 | DB14783 | 0 | 287 | [
"DDInter466",
"DDInter574"
] | Dactinomycin | Diroximel fumarate | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also d... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
0,
24,
287
]
],
[
[
0,
24,
384
],
[
384,
24,
287
]
],
[
[
0,
63,
599
],
[
599,
24,
287
]
],
[
[
0,
25,
770
],
[
770,
24,
2... | [
[
[
"Dactinomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Dactinomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
... | Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzum... |
DB00881 | DB08907 | 954 | 1,344 | [
"DDInter1554",
"DDInter280"
] | Quinapril | Canagliflozin | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
954,
24,
1344
]
],
[
[
954,
24,
549
],
[
549,
1,
1344
]
],
[
[
954,
21,
28962
],
[
28962,
60,
1344
]
],
[
[
954,
24,
1486
],
[
1486,
... | [
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Quinapril (Compound) causes Hyperkalaemia (Side Effect) and Hyperkalaemia (Side Effect) is caused by Canagliflozin (Compound)
Quinapril may cause a mode... |
DB00491 | DB01059 | 127 | 956 | [
"DDInter1217",
"DDInter1313"
] | Miglitol | Norfloxacin | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Moderate | 1 | [
[
[
127,
24,
956
]
],
[
[
127,
24,
872
],
[
872,
40,
956
]
],
[
[
127,
63,
1176
],
[
1176,
1,
956
]
],
[
[
127,
24,
1539
],
[
1539,
... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norfloxacin"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
],
[
... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Norfloxacin (Comp... |
DB00224 | DB08875 | 215 | 1,618 | [
"DDInter917",
"DDInter262"
] | Indinavir | Cabozantinib | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
215,
25,
1618
]
],
[
[
215,
25,
1135
],
[
1135,
62,
1618
]
],
[
[
215,
24,
723
],
[
723,
24,
1618
]
],
[
[
215,
24,
384
],
[
384,
... | [
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may... | Indinavir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a mo... |
DB01018 | DB04837 | 1,364 | 649 | [
"DDInter847",
"DDInter407"
] | Guanfacine | Clofedanol | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approva... | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
1364,
24,
649
]
],
[
[
1364,
24,
1376
],
[
1376,
24,
649
]
],
[
[
1364,
24,
820
],
[
820,
40,
649
]
],
[
[
1364,
63,
1614
],
[
1614,
... | [
[
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
... | Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine... |
DB06081 | DB11689 | 1,046 | 321 | [
"DDInter286",
"DDInter1659"
] | Caplacizumab | Selumetinib | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating ea... | Moderate | 1 | [
[
[
1046,
24,
321
]
],
[
[
1046,
25,
298
],
[
298,
24,
321
]
],
[
[
1046,
64,
291
],
[
291,
24,
321
]
],
[
[
1046,
25,
1421
],
[
1421,
... | [
[
[
"Caplacizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Caplacizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Protein C"
],
[
"Protei... | Caplacizumab may lead to a major life threatening interaction when taken with Protein C and Protein C may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Caplacizumab may lead to a major life threatening interaction when taken with Argatroban and Argatroban may cause a moderate i... |
DB00361 | DB12095 | 134 | 179 | [
"DDInter1939",
"DDInter1760"
] | Vinorelbine | Telotristat ethyl | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
134,
24,
179
]
],
[
[
134,
24,
79
],
[
79,
24,
179
]
],
[
[
134,
24,
283
],
[
283,
63,
179
]
],
[
[
134,
63,
10
],
[
10,
24,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and... |
DB00047 | DB06335 | 176 | 761 | [
"DDInter932",
"DDInter1646"
] | Insulin glargine | Saxagliptin | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
176,
24,
761
]
],
[
[
176,
23,
1103
],
[
1103,
23,
761
]
],
[
[
176,
24,
1491
],
[
1491,
63,
761
]
],
[
[
176,
24,
1577
],
[
1577,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Insulin glargine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
... | Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Saxagliptin
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin ... |
DB08871 | DB09498 | 36 | 810 | [
"DDInter666",
"DDInter1715"
] | Eribulin | Strontium chloride Sr-89 | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
36,
24,
810
]
],
[
[
36,
63,
1555
],
[
1555,
24,
810
]
],
[
[
36,
24,
1060
],
[
1060,
63,
810
]
],
[
[
36,
24,
350
],
[
350,
24,... | [
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
... | Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Enfortuma... |
DB01225 | DB04932 | 500 | 1,564 | [
"DDInter645",
"DDInter491"
] | Enoxaparin | Defibrotide | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Da... | Major | 2 | [
[
[
500,
25,
1564
]
],
[
[
500,
23,
297
],
[
297,
62,
1564
]
],
[
[
500,
64,
914
],
[
914,
24,
1564
]
],
[
[
500,
63,
1039
],
[
1039,
... | [
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
],
[
[
"Enoxaparin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{... | Enoxaparin may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Defibrotide
Enoxaparin may lead to a major life threatening interaction when taken with Diflunisal and Diflunisal may cause a moderate in... |
DB09049 | DB09054 | 1,135 | 384 | [
"DDInter1261",
"DDInter905"
] | Naloxegol | Idelalisib | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Major | 2 | [
[
[
1135,
25,
384
]
],
[
[
1135,
64,
555
],
[
555,
23,
384
]
],
[
[
1135,
62,
307
],
[
307,
23,
384
]
],
[
[
1135,
62,
1618
],
[
1618,
... | [
[
[
"Naloxegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Naloxegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Netupitant"
],
[
"Netupitant",
"{u} may... | Naloxegol may lead to a major life threatening interaction when taken with Netupitant and Netupitant may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Naloxegol may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor ... |
DB00631 | DB06210 | 372 | 72 | [
"DDInter405",
"DDInter631"
] | Clofarabine | Eltrombopag | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Moderate | 1 | [
[
[
372,
24,
72
]
],
[
[
372,
24,
384
],
[
384,
63,
72
]
],
[
[
372,
24,
467
],
[
467,
24,
72
]
],
[
[
372,
63,
289
],
[
289,
24,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Si... |
DB00013 | DB06441 | 1,255 | 936 | [
"DDInter1905",
"DDInter283"
] | Urokinase | Cangrelor | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Major | 2 | [
[
[
1255,
25,
936
]
],
[
[
1255,
23,
1631
],
[
1631,
62,
936
]
],
[
[
1255,
24,
97
],
[
97,
24,
936
]
],
[
[
1255,
24,
643
],
[
643,
... | [
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
]
],
[
[
"Urokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric",
... | Urokinase may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Cangrelor
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin and Oxaprozin may caus... |
DB01319 | DB11921 | 34 | 1,019 | [
"DDInter777",
"DDInter492"
] | Fosamprenavir | Deflazacort | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
34,
25,
1019
]
],
[
[
34,
63,
959
],
[
959,
24,
1019
]
],
[
[
34,
24,
1619
],
[
1619,
63,
1019
]
],
[
[
34,
24,
761
],
[
761,
24... | [
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glip... | Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Ru... |
DB00651 | DB01210 | 746 | 668 | [
"DDInter613",
"DDInter1050"
] | Dyphylline | Levobunolol (ophthalmic) | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | Levobunolol is a cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma. It has a role as an antiglaucoma drug and a beta-adrener... | Major | 2 | [
[
[
746,
25,
668
]
],
[
[
746,
64,
461
],
[
461,
1,
668
]
],
[
[
746,
24,
688
],
[
688,
25,
668
]
],
[
[
746,
25,
887
],
[
887,
1,
... | [
[
[
"Dyphylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levobunolol"
]
],
[
[
"Dyphylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} (Compo... | Dyphylline may lead to a major life threatening interaction when taken with Levobunolol
Dyphylline may lead to a major life threatening interaction when taken with Timolol and Timolol (Compound) resembles Levobunolol (Compound)
Dyphylline may cause a moderate interaction that could exacerbate diseases when taken with S... |
DB00488 | DB08913 | 196 | 1,186 | [
"DDInter57",
"DDInter1561"
] | Altretamine | Radium Ra 223 dichloride | An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first ap... | Moderate | 1 | [
[
[
196,
24,
1186
]
],
[
[
196,
21,
28722
],
[
28722,
60,
1186
]
],
[
[
196,
24,
1362
],
[
1362,
63,
1186
]
],
[
[
196,
63,
599
],
[
599,
... | [
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Altretamine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effec... | Altretamine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with R... |
DB11979 | DB12001 | 1,320 | 564 | [
"DDInter625",
"DDInter7"
] | Elagolix | Abemaciclib | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Moderate | 1 | [
[
[
1320,
24,
564
]
],
[
[
1320,
63,
536
],
[
536,
24,
564
]
],
[
[
1320,
24,
982
],
[
982,
63,
564
]
],
[
[
1320,
24,
484
],
[
484,
... | [
[
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
],
[
... | Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosi... |
DB00280 | DB00283 | 494 | 701 | [
"DDInter575",
"DDInter395"
] | Disopyramide | Clemastine | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Moderate | 1 | [
[
[
494,
24,
701
]
],
[
[
494,
40,
649
],
[
649,
63,
701
]
],
[
[
494,
24,
543
],
[
543,
63,
701
]
],
[
[
494,
6,
8374
],
[
8374,
45... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
]
],
[
[
"Disopyramide",
"{u} (Compound) resembles {v} (Compound)",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a mod... | Disopyramide (Compound) resembles Clofedanol (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Clemastine
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that c... |
DB00030 | DB01136 | 1,685 | 772 | [
"DDInter934",
"DDInter305"
] | Insulin human | Carvedilol | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Moderate | 1 | [
[
[
1685,
24,
772
]
],
[
[
1685,
24,
542
],
[
542,
23,
772
]
],
[
[
1685,
24,
891
],
[
891,
24,
772
]
],
[
[
1685,
24,
1033
],
[
1033,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
],... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Carvedilol
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Prednisolon... |
DB00457 | DB01246 | 1,205 | 820 | [
"DDInter1511",
"DDInter45"
] | Prazosin | Alimemazine | Prazosin is a drug used to treat hypertension. Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988. It belongs to the class of drugs known as alpha-1 antagonists. Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTS... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
1205,
24,
820
]
],
[
[
1205,
24,
104
],
[
104,
40,
820
]
],
[
[
1205,
24,
401
],
[
401,
24,
820
]
],
[
[
1205,
21,
29956
],
[
29956,
... | [
[
[
"Prazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Prazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that ... |
DB00035 | DB00465 | 1,314 | 886 | [
"DDInter507",
"DDInter1010"
] | Desmopressin | Ketorolac | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Moderate | 1 | [
[
[
1314,
24,
886
]
],
[
[
1314,
24,
24
],
[
24,
40,
886
]
],
[
[
1314,
6,
10522
],
[
10522,
45,
886
]
],
[
[
1314,
21,
28936
],
[
28936,
... | [
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketorolac"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolmetin"
],
[
... | Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin and Tolmetin (Compound) resembles Ketorolac (Compound)
Desmopressin (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Ketorolac (Compound)
Desmopressin (Compound) causes Hyperhidrosis (Side Effect) and Hyperhi... |
DB00278 | DB00712 | 291 | 1,274 | [
"DDInter117",
"DDInter763"
] | Argatroban | Flurbiprofen | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Moderate | 1 | [
[
[
291,
24,
1274
]
],
[
[
291,
24,
935
],
[
935,
63,
1274
]
],
[
[
291,
21,
28769
],
[
28769,
60,
1274
]
],
[
[
291,
23,
297
],
[
297,
... | [
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
],
[
... | Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen
Argatroban (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Fl... |
DB00270 | DB09054 | 1,428 | 384 | [
"DDInter993",
"DDInter905"
] | Isradipine | Idelalisib | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1428,
24,
384
]
],
[
[
1428,
63,
58
],
[
58,
24,
384
]
],
[
[
1428,
24,
891
],
[
891,
24,
384
]
],
[
[
1428,
1,
409
],
[
409,
24... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
... | Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Predni... |
DB01041 | DB14711 | 770 | 779 | [
"DDInter1789",
"DDInter1680"
] | Thalidomide | Smallpox (Vaccinia) Vaccine, Live | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
770,
25,
779
]
],
[
[
770,
64,
1064
],
[
1064,
25,
779
]
],
[
[
770,
24,
478
],
[
478,
25,
779
]
],
[
[
770,
25,
1377
],
[
1377,
... | [
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"... | Thalidomide may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib ma... |
DB01281 | DB14783 | 881 | 287 | [
"DDInter5",
"DDInter574"
] | Abatacept | Diroximel fumarate | Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS mo... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
881,
24,
287
]
],
[
[
881,
25,
1583
],
[
1583,
24,
287
]
],
[
[
881,
63,
599
],
[
599,
24,
287
]
],
[
[
881,
24,
270
],
[
270,
2... | [
[
[
"Abatacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
],
[
"Saril... | Abatacept may lead to a major life threatening interaction when taken with Sarilumab and Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Abatacept may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may ... |
DB06077 | DB12500 | 879 | 283 | [
"DDInter1102",
"DDInter714"
] | Lumateperone | Fedratinib | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
879,
25,
283
]
],
[
[
879,
25,
351
],
[
351,
23,
283
]
],
[
[
879,
64,
1419
],
[
1419,
24,
283
]
],
[
[
879,
24,
761
],
[
761,
2... | [
[
[
"Lumateperone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Lumateperone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{... | Lumateperone may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Lumateperone may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate intera... |
DB00283 | DB00662 | 701 | 717 | [
"DDInter395",
"DDInter1873"
] | Clemastine | Trimethobenzamide | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Moderate | 1 | [
[
[
701,
24,
717
]
],
[
[
701,
21,
28762
],
[
28762,
60,
717
]
],
[
[
701,
24,
1382
],
[
1382,
63,
717
]
],
[
[
701,
24,
109
],
[
109,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Clemastine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is... | Clemastine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Trimethobenzamide (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Midazolam and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Trim... |
DB00019 | DB06589 | 1,257 | 1,250 | [
"DDInter1405",
"DDInter1400"
] | Pegfilgrastim | Pazopanib | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
1257,
24,
1250
]
],
[
[
1257,
24,
1419
],
[
1419,
24,
1250
]
],
[
[
1257,
24,
1491
],
[
1491,
63,
1250
]
],
[
[
1257,
24,
384
],
[
384... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Mido... |
DB00014 | DB00539 | 521 | 11 | [
"DDInter839",
"DDInter1837"
] | Goserelin | Toremifene | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Major | 2 | [
[
[
521,
25,
11
]
],
[
[
521,
5,
11579
],
[
11579,
44,
11
]
],
[
[
521,
7,
8924
],
[
8924,
46,
11
]
],
[
[
521,
21,
28646
],
[
28646,
... | [
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
]
],
[
[
"Goserelin",
"{u} (Compound) treats {v} (Disease)",
"breast cancer"
],
[
"breast cancer",
"{u} (Disease) is treated by {v} (Compo... | Goserelin (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Toremifene (Compound)
Goserelin (Compound) upregulates SPAG4 (Gene) and SPAG4 (Gene) is upregulated by Toremifene (Compound)
Goserelin (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Un... |
DB01050 | DB13074 | 848 | 877 | [
"DDInter900",
"DDInter1110"
] | Ibuprofen | Macimorelin | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Moderate | 1 | [
[
[
848,
24,
877
]
],
[
[
848,
64,
1479
],
[
1479,
24,
877
]
],
[
[
848,
24,
913
],
[
913,
24,
877
]
],
[
[
848,
63,
311
],
[
311,
2... | [
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
],
[
"A... | Ibuprofen may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and A... |
DB09312 | DB14783 | 967 | 287 | [
"DDInter103",
"DDInter574"
] | Antilymphocyte immunoglobulin (horse) | Diroximel fumarate | Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
967,
24,
287
]
],
[
[
967,
63,
599
],
[
599,
24,
287
]
],
[
[
967,
24,
270
],
[
270,
24,
287
]
],
[
[
967,
25,
1510
],
[
1510,
2... | [
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate dis... | Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that... |
DB00757 | DB11986 | 1,166 | 484 | [
"DDInter581",
"DDInter648"
] | Dolasetron | Entrectinib | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Major | 2 | [
[
[
1166,
25,
484
]
],
[
[
1166,
23,
1247
],
[
1247,
23,
484
]
],
[
[
1166,
25,
222
],
[
222,
23,
484
]
],
[
[
1166,
25,
1539
],
[
1539,
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Dolasetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfa... | Dolasetron may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Dolasetron may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine... |
DB00552 | DB08904 | 1,238 | 375 | [
"DDInter1425",
"DDInter342"
] | Pentostatin | Certolizumab pegol | A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
1238,
25,
375
]
],
[
[
1238,
24,
200
],
[
200,
63,
375
]
],
[
[
1238,
63,
66
],
[
66,
24,
375
]
],
[
[
1238,
1,
1477
],
[
1477,
... | [
[
[
"Pentostatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
... | Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00794 | DB09291 | 759 | 741 | [
"DDInter1521",
"DDInter1615"
] | Primidone | Rolapitant | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Major | 2 | [
[
[
759,
25,
741
]
],
[
[
759,
25,
1135
],
[
1135,
23,
741
]
],
[
[
759,
63,
506
],
[
506,
24,
741
]
],
[
[
759,
25,
159
],
[
159,
6... | [
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rolapitant"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may c... | Primidone may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may ... |
DB00559 | DB12941 | 152 | 466 | [
"DDInter223",
"DDInter481"
] | Bosentan | Darolutamide | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Moderate | 1 | [
[
[
152,
24,
466
]
],
[
[
152,
63,
600
],
[
600,
23,
466
]
],
[
[
152,
24,
351
],
[
351,
23,
466
]
],
[
[
152,
25,
283
],
[
283,
23,... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
... | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribocicl... |
DB00014 | DB01218 | 521 | 1,493 | [
"DDInter839",
"DDInter852"
] | Goserelin | Halofantrine | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Major | 2 | [
[
[
521,
25,
1493
]
],
[
[
521,
21,
28810
],
[
28810,
60,
1493
]
],
[
[
521,
24,
479
],
[
479,
23,
1493
]
],
[
[
521,
23,
112
],
[
112,
... | [
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Goserelin",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u} (Side Effect... | Goserelin (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Halofantrine (Compound)
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects whe... |
DB00418 | DB09570 | 536 | 1,480 | [
"DDInter1650",
"DDInter1002"
] | Secobarbital | Ixazomib | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
536,
24,
1480
]
],
[
[
536,
24,
310
],
[
310,
24,
1480
]
],
[
[
536,
40,
1023
],
[
1023,
24,
1480
]
],
[
[
536,
24,
214
],
[
214,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Secobarbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a moderate interaction ... |
DB05381 | DB06282 | 172 | 516 | [
"DDInter863",
"DDInter1053"
] | Histamine | Levocetirizine | A depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter. | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
172,
24,
516
]
],
[
[
172,
63,
701
],
[
701,
24,
516
]
],
[
[
172,
24,
337
],
[
337,
63,
516
]
],
[
[
172,
63,
701
],
[
701,
23,... | [
[
[
"Histamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Histamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
... | Histamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Histamine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine an... |
DB04908 | DB08865 | 1,671 | 1,593 | [
"DDInter741",
"DDInter448"
] | Flibanserin | Crizotinib | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
1671,
25,
1593
]
],
[
[
1671,
25,
283
],
[
283,
62,
1593
]
],
[
[
1671,
24,
1409
],
[
1409,
24,
1593
]
],
[
[
1671,
24,
710
],
[
710,
... | [
[
[
"Flibanserin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Flibanserin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u}... | Flibanserin may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a mo... |
DB01263 | DB09272 | 859 | 412 | [
"DDInter1494",
"DDInter632"
] | Posaconazole | Eluxadoline | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
859,
24,
412
]
],
[
[
859,
64,
543
],
[
543,
24,
412
]
],
[
[
859,
24,
1374
],
[
1374,
24,
412
]
],
[
[
859,
25,
1478
],
[
1478,
... | [
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Loperamide"
],
[
"Loper... | Posaconazole may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may... |
DB00812 | DB04845 | 998 | 309 | [
"DDInter1451",
"DDInter1001"
] | Phenylbutazone | Ixabepilone | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Moderate | 1 | [
[
[
998,
24,
309
]
],
[
[
998,
6,
8374
],
[
8374,
45,
309
]
],
[
[
998,
40,
307
],
[
307,
23,
309
]
],
[
[
998,
63,
1419
],
[
1419,
... | [
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Phenylbutazone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Co... | Phenylbutazone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ixabepilone (Compound)
Phenylbutazone (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Ixabepilone
Phenylbutazone may cause a moderate interaction that could e... |
DB00439 | DB00515 | 289 | 589 | [
"DDInter341",
"DDInter387"
] | Cerivastatin | Cisplatin | On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Cana... | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Moderate | 1 | [
[
[
289,
24,
589
]
],
[
[
289,
24,
1468
],
[
1468,
63,
589
]
],
[
[
289,
63,
367
],
[
367,
24,
589
]
],
[
[
289,
24,
63
],
[
63,
24,... | [
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
... | Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1... |
DB01267 | DB09330 | 519 | 985 | [
"DDInter1381",
"DDInter1352"
] | Paliperidone | Osimertinib | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
519,
25,
985
]
],
[
[
519,
62,
112
],
[
112,
23,
985
]
],
[
[
519,
63,
480
],
[
480,
24,
985
]
],
[
[
519,
24,
657
],
[
657,
63,... | [
[
[
"Paliperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Paliperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Paliperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and... |
DB00327 | DB00748 | 421 | 662 | [
"DDInter890",
"DDInter297"
] | Hydromorphone | Carbinoxamine | Hydromorphone is a pure opioid, a semi-synthetic hydrogenated ketone derivative of [morphine] that has been available clinically since 1920. Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 a... | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
421,
24,
662
]
],
[
[
421,
24,
1594
],
[
1594,
24,
662
]
],
[
[
421,
6,
6017
],
[
6017,
45,
662
]
],
[
[
421,
21,
28921
],
[
28921,
... | [
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],... | Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Hydromorphone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Carbinoxamine (Compound)
Hydrom... |
DB00938 | DB04946 | 455 | 924 | [
"DDInter1635",
"DDInter907"
] | Salmeterol | Iloperidone | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Moderate | 1 | [
[
[
455,
24,
924
]
],
[
[
455,
63,
1664
],
[
1664,
1,
924
]
],
[
[
455,
63,
1425
],
[
1425,
25,
924
]
],
[
[
455,
24,
519
],
[
519,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Cisapride and Cisapride may lead to a major life threatening inter... |
DB00590 | DB00852 | 1,433 | 1,445 | [
"DDInter592",
"DDInter1545"
] | Doxazosin | Pseudoephedrine | Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin]. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfi... | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Moderate | 1 | [
[
[
1433,
24,
1445
]
],
[
[
1433,
6,
5214
],
[
5214,
45,
1445
]
],
[
[
1433,
21,
28763
],
[
28763,
60,
1445
]
],
[
[
1433,
24,
1344
],
[
1... | [
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
]
],
[
[
"Doxazosin",
"{u} (Compound) binds {v} (Gene)",
"ADRA1A"
],
[
"ADRA1A",
"{u} (Gene) is bound by {v} (Compound... | Doxazosin (Compound) binds ADRA1A (Gene) and ADRA1A (Gene) is bound by Pseudoephedrine (Compound)
Doxazosin (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Pseudoephedrine (Compound)
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Canagliflo... |
DB00816 | DB00845 | 1,674 | 1,490 | [
"DDInter1346",
"DDInter406"
] | Orciprenaline | Clofazimine | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Moderate | 1 | [
[
[
1674,
24,
1490
]
],
[
[
1674,
21,
28703
],
[
28703,
60,
1490
]
],
[
[
1674,
24,
1250
],
[
1250,
63,
1490
]
],
[
[
1674,
63,
51
],
[
51... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofazimine"
]
],
[
[
"Orciprenaline",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is... | Orciprenaline (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Clofazimine (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Clof... |
DB01105 | DB09045 | 222 | 52 | [
"DDInter1665",
"DDInter607"
] | Sibutramine | Dulaglutide | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
222,
24,
52
]
],
[
[
222,
24,
170
],
[
170,
23,
52
]
],
[
[
222,
24,
280
],
[
280,
24,
52
]
],
[
[
222,
23,
609
],
[
609,
24,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Mephentermine and ... |
DB00640 | DB01001 | 1,585 | 688 | [
"DDInter31",
"DDInter1632"
] | Adenosine | Salbutamol | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
1585,
24,
688
]
],
[
[
1585,
21,
28714
],
[
28714,
60,
688
]
],
[
[
1585,
25,
1069
],
[
1069,
63,
688
]
],
[
[
1585,
24,
1297
],
[
129... | [
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Adenosine",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused b... | Adenosine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Salbutamol (Compound)
Adenosine may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Adenosine may c... |
DB00983 | DB01276 | 480 | 123 | [
"DDInter776",
"DDInter706"
] | Formoterol | Exenatide | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
480,
24,
123
]
],
[
[
480,
74,
532
],
[
532,
24,
123
]
],
[
[
480,
63,
1636
],
[
1636,
24,
123
]
],
[
[
480,
23,
708
],
[
708,
6... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Formoterol",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken wi... | Formoterol (Compound) resembles Dobutamine (Compound) and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Dobutamine and Dobutamine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Formoterol may cause a moderate interaction that could ... |
DB00270 | DB01222 | 1,428 | 617 | [
"DDInter993",
"DDInter246"
] | Isradipine | Budesonide | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
1428,
24,
617
]
],
[
[
1428,
24,
251
],
[
251,
1,
617
]
],
[
[
1428,
6,
8374
],
[
8374,
45,
617
]
],
[
[
1428,
18,
3106
],
[
3106,
... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[... | Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Isradipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Budesonide (Compound)
Isradipine (Compound) downregulates DNAJA3 (Gene) and DNAJA3... |
DB00186 | DB06691 | 905 | 849 | [
"DDInter1092",
"DDInter1155"
] | Lorazepam | Mepyramine | Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
905,
24,
849
]
],
[
[
905,
24,
1594
],
[
1594,
24,
849
]
],
[
[
905,
40,
1119
],
[
1119,
24,
849
]
],
[
[
905,
24,
1074
],
[
1074,
... | [
[
[
"Lorazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Lorazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Lorazepam may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Lorazepam (Compound) resembles Chlordiazepoxide (Compound) and Chlordiazepoxide may cause a moderate interaction ... |
DB05578 | DB06754 | 330 | 707 | [
"DDInter1566",
"DDInter471"
] | Ramucirumab | Danaparoid | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity t... | Major | 2 | [
[
[
330,
25,
707
]
],
[
[
330,
25,
1004
],
[
1004,
63,
707
]
],
[
[
330,
24,
41
],
[
41,
63,
707
]
],
[
[
330,
63,
901
],
[
901,
24,... | [
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenyl salicylate"
],
[
"Phenyl salicylat... | Ramucirumab may lead to a major life threatening interaction when taken with Phenyl salicylate and Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Ramucirumab may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and ... |
DB01172 | DB01181 | 416 | 1,532 | [
"DDInter1004",
"DDInter906"
] | Kanamycin | Ifosfamide | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
416,
24,
1532
]
],
[
[
416,
21,
28748
],
[
28748,
60,
1532
]
],
[
[
416,
74,
1132
],
[
1132,
24,
1532
]
],
[
[
416,
63,
372
],
[
372,
... | [
[
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Kanamycin",
"{u} (Compound) causes {v} (Side Effect)",
"Vertigo"
],
[
"Vertigo",
"{u} (Side Effect) is caused by ... | Kanamycin (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Ifosfamide (Compound)
Kanamycin (Compound) resembles Gentamicin (Compound) and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may cause a moderate interaction tha... |
DB01067 | DB01403 | 959 | 9 | [
"DDInter826",
"DDInter1175"
] | Glipizide | Methotrimeprazine | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Moderate | 1 | [
[
[
959,
24,
9
]
],
[
[
959,
63,
1178
],
[
1178,
40,
9
]
],
[
[
959,
63,
1164
],
[
1164,
1,
9
]
],
[
[
959,
24,
401
],
[
401,
24,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]... | Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Met... |
DB00307 | DB09083 | 1,101 | 880 | [
"DDInter202",
"DDInter996"
] | Bexarotene | Ivabradine | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Moderate | 1 | [
[
[
1101,
24,
880
]
],
[
[
1101,
24,
1478
],
[
1478,
24,
880
]
],
[
[
1101,
24,
159
],
[
159,
63,
880
]
],
[
[
1101,
23,
1040
],
[
1040,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larot... |
DB00204 | DB00261 | 228 | 702 | [
"DDInter580",
"DDInter93"
] | Dofetilide | Anagrelide | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Major | 2 | [
[
[
228,
25,
702
]
],
[
[
228,
21,
29316
],
[
29316,
60,
702
]
],
[
[
228,
23,
112
],
[
112,
62,
702
]
],
[
[
228,
24,
659
],
[
659,
... | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
]
],
[
[
"Dofetilide",
"{u} (Compound) causes {v} (Side Effect)",
"Sweating"
],
[
"Sweating",
"{u} (Side Effect) is caused by {v} (Compou... | Dofetilide (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Anagrelide (Compound)
Dofetilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Anagrel... |
DB00424 | DB11859 | 19 | 418 | [
"DDInter896",
"DDInter230"
] | Hyoscyamine | Brexanolone | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically for the treatment of postpartum depression (PPD) in adult females . Since PPD, like various other types of depr... | Moderate | 1 | [
[
[
19,
24,
418
]
],
[
[
19,
24,
820
],
[
820,
24,
418
]
],
[
[
19,
63,
999
],
[
999,
24,
418
]
],
[
[
19,
24,
820
],
[
820,
63,
... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine... |
DB00526 | DB06414 | 1,555 | 655 | [
"DDInter1355",
"DDInter703"
] | Oxaliplatin | Etravirine | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Moderate | 1 | [
[
[
1555,
24,
655
]
],
[
[
1555,
24,
786
],
[
786,
40,
655
]
],
[
[
1555,
63,
168
],
[
168,
23,
655
]
],
[
[
1555,
24,
1151
],
[
1151,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
],
[... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine and Rilpivirine (Compound) resembles Etravirine (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can ... |
DB00108 | DB13985 | 1,066 | 546 | [
"DDInter1268",
"DDInter1108"
] | Natalizumab | Lutetium Lu 177 dotatate | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dot... | Major | 2 | [
[
[
1066,
25,
546
]
],
[
[
1066,
64,
66
],
[
66,
24,
546
]
],
[
[
1066,
25,
1683
],
[
1683,
24,
546
]
],
[
[
1066,
24,
267
],
[
267,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Efalizumab"
],
[
"Efalizuma... | Natalizumab may lead to a major life threatening interaction when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Natalizumab may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may cau... |
DB00341 | DB00564 | 1,242 | 1,236 | [
"DDInter343",
"DDInter293"
] | Cetirizine | Carbamazepine | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Moderate | 1 | [
[
[
1242,
24,
1236
]
],
[
[
1242,
24,
1405
],
[
1405,
40,
1236
]
],
[
[
1242,
24,
508
],
[
508,
1,
1236
]
],
[
[
1242,
63,
362
],
[
362,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine (Compound) resembles Carbamazepine (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Carbamazepi... |
DB00661 | DB01259 | 122 | 392 | [
"DDInter1928",
"DDInter1024"
] | Verapamil | Lapatinib | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
122,
24,
392
]
],
[
[
122,
6,
4973
],
[
4973,
45,
392
]
],
[
[
122,
18,
3106
],
[
3106,
57,
392
]
],
[
[
122,
21,
29539
],
[
29539,
... | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Verapamil",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Verapamil (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Verapamil (Compound) downregulates DNAJA3 (Gene) and DNAJA3 (Gene) is downregulated by Lapatinib (Compound)
Verapamil (Compound) causes Hepatotoxicity (Side Effect) and Hepatotoxicity (Side Effect) is caused by Lapatinib (Compound... |
DB00264 | DB11921 | 88 | 1,019 | [
"DDInter1200",
"DDInter492"
] | Metoprolol | Deflazacort | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
88,
24,
1019
]
],
[
[
88,
24,
959
],
[
959,
24,
1019
]
],
[
[
88,
23,
286
],
[
286,
24,
1019
]
],
[
[
88,
40,
887
],
[
887,
24,
... | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Metoprolol may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and ... |
DB06077 | DB12130 | 879 | 1,017 | [
"DDInter1102",
"DDInter1094"
] | Lumateperone | Lorlatinib | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Major | 2 | [
[
[
879,
25,
1017
]
],
[
[
879,
64,
1101
],
[
1101,
23,
1017
]
],
[
[
879,
63,
590
],
[
590,
24,
1017
]
],
[
[
879,
24,
549
],
[
549,
... | [
[
[
"Lumateperone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Lumateperone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{... | Lumateperone may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide ma... |
DB01159 | DB12010 | 419 | 214 | [
"DDInter854",
"DDInter785"
] | Halothane | Fostamatinib | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
419,
24,
214
]
],
[
[
419,
63,
51
],
[
51,
24,
214
]
],
[
[
419,
24,
1250
],
[
1250,
24,
214
]
],
[
[
419,
64,
1031
],
[
1031,
2... | [
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
[
... | Halothane may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Paz... |
DB00615 | DB06772 | 690 | 310 | [
"DDInter1589",
"DDInter259"
] | Rifabutin | Cabazitaxel | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
690,
24,
310
]
],
[
[
690,
24,
973
],
[
973,
24,
310
]
],
[
[
690,
6,
8374
],
[
8374,
45,
310
]
],
[
[
690,
21,
28646
],
[
28646,
... | [
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Rifabutin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cabazitaxel (Compound)
Rifabutin (Compoun... |
DB00853 | DB11817 | 1,686 | 1,259 | [
"DDInter1762",
"DDInter165"
] | Temozolomide | Baricitinib | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
1686,
25,
1259
]
],
[
[
1686,
63,
1461
],
[
1461,
23,
1259
]
],
[
[
1686,
24,
949
],
[
949,
24,
1259
]
],
[
[
1686,
24,
1129
],
[
1129... | [
[
[
"Temozolomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitami... | Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani t... |
DB00810 | DB00981 | 456 | 1,528 | [
"DDInter211",
"DDInter1462"
] | Biperiden | Physostigmine | A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. | A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. | Moderate | 1 | [
[
[
456,
24,
1528
]
],
[
[
456,
24,
1511
],
[
1511,
63,
1528
]
],
[
[
456,
24,
543
],
[
543,
24,
1528
]
],
[
[
456,
1,
1386
],
[
1386,
... | [
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
... | Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Lop... |
DB04868 | DB04938 | 478 | 1,423 | [
"DDInter1293",
"DDInter1353"
] | Nilotinib | Ospemifene | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013. | Moderate | 1 | [
[
[
478,
24,
1423
]
],
[
[
478,
64,
485
],
[
485,
40,
1423
]
],
[
[
478,
6,
6017
],
[
6017,
45,
1423
]
],
[
[
478,
21,
28883
],
[
28883,
... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ospemifene"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
],
[
"Pentamidine... | Nilotinib may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine (Compound) resembles Ospemifene (Compound)
Nilotinib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Ospemifene (Compound)
Nilotinib (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side E... |
DB00023 | DB00766 | 305 | 1,675 | [
"DDInter127",
"DDInter394"
] | Asparaginase Escherichia coli | Clavulanic acid | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Clavulanic acid is a beta-lactamase inhibitor that is frequently combined with [Amoxicillin] or [Ticarcillin] to fight antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening their spectrum of susceptible bacterial infections. Clavulanic acid is derived from the organism Streptomyces... | Moderate | 1 | [
[
[
305,
24,
1675
]
],
[
[
305,
24,
850
],
[
850,
63,
1675
]
],
[
[
305,
24,
482
],
[
482,
24,
1675
]
],
[
[
305,
25,
1377
],
[
1377,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clavulanic acid"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken wi... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Clavulanic acid
Asparaginase Escherichia coli may cause a moderate interaction that co... |
DB00489 | DB08907 | 17 | 1,344 | [
"DDInter1704",
"DDInter280"
] | Sotalol | Canagliflozin | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
17,
24,
1344
]
],
[
[
17,
24,
549
],
[
549,
1,
1344
]
],
[
[
17,
21,
28680
],
[
28680,
60,
1344
]
],
[
[
17,
24,
1445
],
[
1445,
... | [
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
... | Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Sotalol (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Canagliflozin (Compound)
Sotalol may cause a moderate interaction that co... |
DB00572 | DB01403 | 85 | 9 | [
"DDInter136",
"DDInter1175"
] | Atropine | Methotrimeprazine | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Moderate | 1 | [
[
[
85,
24,
9
]
],
[
[
85,
24,
1178
],
[
1178,
40,
9
]
],
[
[
85,
24,
1164
],
[
1164,
1,
9
]
],
[
[
85,
24,
401
],
[
401,
24,
... | [
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
... | Atropine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound)
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Metho... |
DB00496 | DB01234 | 194 | 1,220 | [
"DDInter480",
"DDInter513"
] | Darifenacin | Dexamethasone | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
194,
24,
1220
]
],
[
[
194,
6,
8374
],
[
8374,
45,
1220
]
],
[
[
194,
7,
12149
],
[
12149,
46,
1220
]
],
[
[
194,
21,
28769
],
[
28769... | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Darifenacin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Darifenacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dexamethasone (Compound)
Darifenacin (Compound) upregulates WRB (Gene) and WRB (Gene) is upregulated by Dexamethasone (Compound)
Darifenacin (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Dexametha... |
DB00331 | DB05294 | 1,645 | 1,069 | [
"DDInter1164",
"DDInter1917"
] | Metformin | Vandetanib | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Moderate | 1 | [
[
[
1645,
24,
1069
]
],
[
[
1645,
7,
2065
],
[
2065,
45,
1069
]
],
[
[
1645,
21,
28883
],
[
28883,
60,
1069
]
],
[
[
1645,
24,
1194
],
[
1... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
]
],
[
[
"Metformin",
"{u} (Compound) upregulates {v} (Gene)",
"SRC"
],
[
"SRC",
"{u} (Gene) is bound by {v} (Compound)",
... | Metformin (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Vandetanib (Compound)
Metformin (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Vandetanib (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.